Passive targeting of nanoparticles to cancer: A comprehensive review of the literature

Bazak,Remon; Houri,Mohamad; El Achy,Samar; Hussein,Wael; Refaat,Tamer

doi:10.3892/mco.2014.356

Passive targeting of nanoparticles to cancer: A comprehensive review of the literature

Authors:
- Remon Bazak
- Mohamad Houri
- Samar El Achy
- Wael Hussein
- Tamer Refaat
View Affiliations

Affiliations: Department of Otorhinolaryngology, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt, Department of Ophthalmology, Faculty of Medicine, Beirut Arab University, Beirut 1107 2809, Lebanon, Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt, Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Alexandria University, Alexandria 21131, Egypt
Published online on: July 23, 2014 https://doi.org/10.3892/mco.2014.356
Pages: 904-908

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cancer remains the one of the most common causes of mortality in humans; thus, cancer treatment is currently a major focus of investigation. Researchers worldwide have been searching for the optimal treatment (the ‘magic bullet’) that will selectively target cancer, without afflicting significant morbidity. Recent advances in cancer nanotechnology have raised exciting opportunities for specific drug delivery by an emerging class of nanotherapeutics that may be targeted to neoplastic cells, thereby offering a major advantage over conventional chemotherapeutic agents. There are two ways by which targeting of nanoparticles may be achieved, namely passive and active targeting. The aim of this study was to provide a comprehensive review of the literature focusing on passive targeting.

View Figures

View References

1	Greish K: Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target. 15:457–464. 2007. View Article : Google Scholar : PubMed/NCBI
2	Greish K: Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol. 624:25–37. 2010. View Article : Google Scholar : PubMed/NCBI
3	LaRocque J, Bharali DJ and Mousa SA: Cancer detection and treatment: the role of nanomedicines. Mol Biotechnol. 42:358–366. 2009. View Article : Google Scholar : PubMed/NCBI
4	Wang X, Wang Y, Chen ZG and Shin DM: Advances of cancer therapy by nanotechnology. Cancer Res Treat. 41:1–11. 2009. View Article : Google Scholar : PubMed/NCBI
5	Kreuter J: Nanoparticles - a historical perspective. Int J Pharm. 331:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
6	Byrne JD, Betancourt T and Brannon-Peppas L: Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 60:1615–1626. 2008. View Article : Google Scholar : PubMed/NCBI
7	Maeda H and Matsumura Y: Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst. 6:193–210. 1989.PubMed/NCBI
8	Matsumura Y and Maeda H: A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46:6387–6392. 1986.
9	Maeda H, Matsumura Y and Oda T: Cancer selective macromolecular therapeutics: tailoring of an antitumor protein drug. Protein Tailoring for Food and Medical Uses. Feeny RE and Whitaker JR: Marcel Dekker, Inc; New York: pp. 353–382. 1986
10	Maeda H, Takeshita J and Kanamaru R: A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int J Pept Protein Res. 14:81–87. 1979. View Article : Google Scholar : PubMed/NCBI
11	Maeda H: Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci. 88:53–71. 2012. View Article : Google Scholar : PubMed/NCBI
12	Cho K, Wang X, Nie S, Chen ZG and Shin DM: Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 14:1310–1316. 2008. View Article : Google Scholar : PubMed/NCBI
13	Iyer AK, Khaled G, Fang J and Maeda H: Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 11:812–818. 2006. View Article : Google Scholar : PubMed/NCBI
14	Skinner SA, Tutton PJ and O’Brien PE: Microvascular architecture of experimental colon tumors in the rat. Cancer Res. 50:2411–2417. 1990.PubMed/NCBI
15	Talekar M, Kendall J, Denny W and Garg S: Targeting of nanoparticles in cancer: drug delivery and diagnostics. Anticancer Drugs. 22:949–962. 2011. View Article : Google Scholar : PubMed/NCBI
16	Kuruppu D, Christophi C, Maeda H and O’Brien PE: Changes in the microvascular architecture of colorectal liver metastases following the administration of SMANCS/lipiodol. J Surg Res. 103:47–54. 2002. View Article : Google Scholar : PubMed/NCBI
17	Suzuki M, Hori K, Abe I, Saito S and Sato H: A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst. 67:663–669. 1981.PubMed/NCBI
18	Li CJ, Miyamoto Y, Kojima Y and Maeda H: Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br J Cancer. 67:975–980. 1993. View Article : Google Scholar : PubMed/NCBI
19	Wu J, Akaike T and Maeda H: Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58:159–165. 1998.PubMed/NCBI
20	Maeda H: The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 41:189–207. 2001. View Article : Google Scholar : PubMed/NCBI
21	Seki T, Fang J and Maeda H: Tumor-targeted macromolecular drug delivery based on the enhanced permeability and retention effect in solid tumor. Pharmaceutical Perspectives of Cancer Therapeutics. Lu Y and Mahato RI: Springer; New York: pp. 93–120. 2009, View Article : Google Scholar
22	Wu J, Akaike T, Hayashida K, Miyamoto Y, Nakagawa T, Miyakawa K, Müller-Esterl W and Maeda H: Identification of bradykinin receptors in clinical cancer specimens and murine tumor tissues. Int J Cancer. 98:29–35. 2002. View Article : Google Scholar : PubMed/NCBI
23	Bhoola K, Ramsaroop R, Plendl J, Cassim B, Dlamini Z and Naicker S: Kallikrein and kinin receptor expression in inflammation and cancer. Biol Chem. 382:77–89. 2001. View Article : Google Scholar : PubMed/NCBI
24	Matsumura Y, Kimura M, Yamamoto T and Maeda H: Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn J Cancer Res. 79:1327–1334. 1988. View Article : Google Scholar : PubMed/NCBI
25	Kou R, Greif D and Michel T: Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J Biol Chem. 277:29669–29673. 2002. View Article : Google Scholar : PubMed/NCBI
26	Papapetropoulos A, Garcia-Cardena G, Madri JA and Sessa WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest. 100:3131–3139. 1997. View Article : Google Scholar
27	Maeda H, Wu J, Okamoto T, et al: Kallikrein-kinin in infection and cancer. Immunopharmacology. 43:115–128. 1999. View Article : Google Scholar : PubMed/NCBI
28	Hori K, Saito S, Takahashi H, Sato H, Maeda H and Sato Y: Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn J Cancer Res. 91:261–269. 2000. View Article : Google Scholar : PubMed/NCBI
29	Noguchi A, Takahashi T, Yamaguchi T, et al: Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. Jpn J Cancer Res. 83:240–243. 1992. View Article : Google Scholar : PubMed/NCBI
30	Maeda H, Fang J, Inutsuka T and Kitamoto Y: Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol. 3:319–328. 2003. View Article : Google Scholar : PubMed/NCBI
31	Maeda H, Noguchi Y, Sato K and Akaike T: Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res. 85:331–334. 1994. View Article : Google Scholar
32	Okamoto T, Akaike T, Sawa T, Miyamoto Y, van der Vliet A and Maeda H: Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem. 276:29596–29602. 2001. View Article : Google Scholar : PubMed/NCBI
33	Maeda H: Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: analogy between angina pectoris and solid tumors and enhancement of the EPR effect. J Control Release. 142:296–298. 2010. View Article : Google Scholar
34	Seki T, Fang J and Maeda H: Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci. 100:2426–2430. 2009. View Article : Google Scholar : PubMed/NCBI
35	Yasuda H, Yamaya M, Nakayama K, et al: Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 24:688–694. 2006. View Article : Google Scholar : PubMed/NCBI
36	Yasuda H, Nakayama K, Watanabe M, et al: Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res. 12:6748–6757. 2006. View Article : Google Scholar : PubMed/NCBI
37	Siemens DR, Heaton JP, Adams MA, Kawakami J and Graham CH: Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology. 74:878–883. 2009. View Article : Google Scholar : PubMed/NCBI
38	Himelstein BP, Canete-Soler R, Bernhard EJ, Dilks DW and Muschel RJ: Metalloproteinases in tumor progression: the contribution of MMP-9. Invasion Metastasis. 14:246–258. 1994.PubMed/NCBI
39	Chambers AF and Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
40	Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A and Maeda H: Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases. Jpn J Cancer Res. 92:439–451. 2001. View Article : Google Scholar : PubMed/NCBI
41	Tanaka S, Akaike T, Wu J, Fang J, Sawa T, Ogawa M, et al: Modulation of tumor-selective vascular blood flow and extravasation by the stable prostaglandin 12 analogue beraprost sodium. J Drug Target. 11:45–52. 2003. View Article : Google Scholar : PubMed/NCBI
42	Moghimi SM, Hunter AC and Murray JC: Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev. 53:283–318. 2001.PubMed/NCBI
43	Huynh NT, Roger E, Lautram N, Benoit JP and Passirani C: The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting. Nanomedicine (Lond). 5:1415–1433. 2010. View Article : Google Scholar : PubMed/NCBI
44	Wang M and Thanou M: Targeting nanoparticles to cancer. Pharmacol Res. 62:90–99. 2010. View Article : Google Scholar
45	Singh R and Lillard JW Jr: Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 86:215–223. 2009. View Article : Google Scholar : PubMed/NCBI
46	Torchilin VP: Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 197:3–53. 2010. View Article : Google Scholar : PubMed/NCBI
47	Fang J, Nakamura H and Maeda H: The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 63:136–151. 2011. View Article : Google Scholar : PubMed/NCBI